Frequently Asked Questions about Incyte Corporation (INCY)

Name: Incyte Corporation (INCY) Institutional Financial Dataset
Creator: Olyth
License: https://olyth.xyz

Question 1

What does Incyte Corporation (INCY) do?

Accepted Answer

Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growt...

Question 2

Is Incyte Corporation (INCY) a good stock to buy?

Accepted Answer

Olyth's institutional analysis of INCY reveals an Altman Z-Score of 8.60 and a Piotroski F-Score of 6/9. These metrics, combined with its 5-year revenue trend ($5.14B most recent), help investors decide if INCY fits their risk profile.

Question 3

What is the current P/E ratio for INCY?

Accepted Answer

As of the latest trading session, Incyte Corporation (INCY) has a trailing P/E ratio of 14.71.

Question 4

Who is the CEO of Incyte Corporation?

Accepted Answer

The current Chief Executive Officer of Incyte Corporation is William J. Meury.

Question 5

What was INCY's revenue for the last 5 years?

Accepted Answer

According to its latest income statements, Incyte Corporation reported annual revenues of $5.14B (2025), $4.24B (2024), $3.70B (2023), $3.39B (2022), $2.99B (2021) respectively.

Question 6

Does INCY pay a dividend?

Accepted Answer

Incyte Corporation does not currently pay a dividend to its shareholders.

Question 7

How much debt and cash flow does INCY have?

Accepted Answer

In its latest reporting period, Incyte Corporation generated $1.35B in Free Cash Flow against a total debt load of $0.07B.

Question 8

What is the Price-to-Book (P/B) ratio of Incyte Corporation?

Accepted Answer

The Price-to-Book (P/B) ratio for Incyte Corporation (INCY) is currently 3.66.

Question 9

What is the Price-to-Sales (P/S) ratio of INCY?

Accepted Answer

Based on trailing twelve-month data, Incyte Corporation (INCY) trades at a Price-to-Sales (P/S) ratio of 3.71.

Question 10

What is Incyte Corporation's Return on Equity (ROE)?

Accepted Answer

Incyte Corporation (INCY) has a Return on Equity (ROE) of 29.15%, representing its profitability relative to shareholder equity.

Period	Total Assets	Total Liabilities	Total Equity	Total Debt	Net Debt
2025-12	7B	1.8B	5.2B	69.4M	-3B
2024-12	5.4B	2B	3.4B	43.5M	-1.6B
2023-12	6.8B	1.6B	5.2B	38.3M	-3.2B
2022-12	5.8B	1.5B	4.4B	41.5M	-2.9B
2021-12	4.9B	1.2B	3.8B	44.8M	-2B